Patents by Inventor Mahima Datla

Mahima Datla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210017300
    Abstract: The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.
    Type: Application
    Filed: September 28, 2020
    Publication date: January 21, 2021
    Inventors: Ramesh Venkat Matur, Vivek Babu Kandimalla, Narender Dev Mantena, Mahima Datla, Muthyala Venkateswara Reddy, Kantam Charan
  • Publication number: 20210009641
    Abstract: The present invention relates to expression of Pneumococcal Surface Protein A (PspA). The invention represents an advancement in the field of genetic engineering and vaccine technology. The invention discloses expression vectors and recombinant host cells for expression of truncated PspA peptide. The invention also discloses vaccine compositions comprising the truncated peptides as carrier protein.
    Type: Application
    Filed: March 1, 2019
    Publication date: January 14, 2021
    Inventors: Rajan Sriraman, Ramesh Venkat Matur, Narender Dev Mantena, Mahima Datla, Swetha Kamireddy
  • Patent number: 10836839
    Abstract: The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: November 17, 2020
    Assignee: BIOLOGICAL E LIMITED
    Inventors: Ramesh Venkat Matur, Vivek Babu Kandimalla, Narender Dev Mantena, Mahima Datla, Muthyala Venkateswara Reddy, Kantam Charan
  • Publication number: 20200277341
    Abstract: The present invention provides an improved method for the production of CRM197 with high yield using engineered Corynebacterium diphtheria strain having an increased copy number of the CRM197 gene, wherein the method comprises growing the strain in media free of animal-derived components with one or more amino acids.
    Type: Application
    Filed: April 19, 2018
    Publication date: September 3, 2020
    Inventors: Balamurali Masilamani, Rajan Sriraman, Mandar Shirish Dixit, Deviprasanna Chakka, Satyam Naidu Sureddi, Ramesh Venkat Matur, Narender Dev Mantena, Mahima Datla
  • Patent number: 10744200
    Abstract: The present invention relates to an improved process for production of Aluminium phosphate (AlPhos) gel wherein the solutions of aluminium salt and alkaline phosphate salt are added to water by maintaining the pH under stirring to obtain the precipitate, followed by sterilization of the said precipitate and finally obtaining the Aluminum phosphate gel.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: August 18, 2020
    Assignee: BIOLOGICAL E LIMITED
    Inventors: Ravi Ganapathy, Nagireddy Gade, Manish Manohar, Vikram Madhusadan Paradkar, Mahima Datla
  • Publication number: 20190389894
    Abstract: The present invention relates to novel semi-synthetic meningococcal conjugate vaccine comprising novel synthetic oligosaccharide conjugated to a carrier protein. The present invention also relates to novel synthetic meningococcal oligosaccharide and a process for its preparation.
    Type: Application
    Filed: June 11, 2019
    Publication date: December 26, 2019
    Inventors: Akshay Goel, Santosh Renukuntla, Eswara Kowlakuntla, Mahima Datla, Narender Dev Mantena
  • Publication number: 20190240308
    Abstract: The present invention relates to a multivalent Pneumococcal conjugate vaccine (PCV) composition comprising: 1) at least 12 capsular polysaccharides selected from serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F of S. pneumoniae activated with CDAP and conjugated to carrier protein selected from CRM197, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA) or combination thereof and 2) a pharmaceutically acceptable carrier, wherein the composition does not contain capsular polysaccharide from serotype 6A.
    Type: Application
    Filed: June 21, 2016
    Publication date: August 8, 2019
    Inventors: Ramesh Venkat Matur, Nagarajan Thirumeni, Rajendar Burki, Narender Dev Mantena, Mahima Datla
  • Publication number: 20190240322
    Abstract: The present invention relates to an improved process for production of Aluminium phosphate (AlPhos) gel wherein the solutions of aluminium salt and alkaline phosphate salt are added to water by maintaining the pH under stirring to obtain the precipitate, followed by sterilization of the said precipitate and finally obtaining the Aluminum phosphate gel.
    Type: Application
    Filed: June 13, 2016
    Publication date: August 8, 2019
    Inventors: Ravi Ganapathy, Nagireddy Gade, Manish Manohar, Vikram Madhusadan Paradkar, Mahima Datla
  • Publication number: 20190224295
    Abstract: The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Inventors: Ramesh Venkat Matur, Rajan Sriraman, Deviprasanna Chakka, Satyam Naidu Sureddi, Rajendar Burki, Sreenivasa Rao Ganti, Narender Dev Mantena, Mahima Datla
  • Patent number: 10280409
    Abstract: The present invention relates to high level expression of bacterial toxoid or toxin protein of pharmacological interest by means of an optimized novel polynucleotide sequence and host transformed with the said polynucleotide. Specifically, the invention provides a method for high production of polypeptide CRM197 wherein, the polynucleotide of the invention is used to transform a suitable host resulting in over-expression of corresponding proteins and a method for isolating the expressed polypeptide. More particularly, the present invention relates to high level expression of CRM197 in Escherichia coli and a method for the isolation and purification thereof.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 7, 2019
    Assignee: BIOLOGICAL E LIMITED
    Inventors: Akshay Goel, Ravi Pratap Narayan Mishra, Narender Dev Mantena, Mahima Datla
  • Publication number: 20180327457
    Abstract: The present invention relates to a preparation method which is performed by expressing the recombinant carrier proteins in Escherichia coli and purification thereof. More particular, the invention relates to industrially scalable process for the recovery of recombinant carrier proteins.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 15, 2018
    Inventors: Akshay Goel, Tushar Joglekar, Krishnanand Tiwari, Yogesh Mishra, Narender Dev Mantena, Mahima Datla
  • Publication number: 20180155453
    Abstract: The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.
    Type: Application
    Filed: April 25, 2016
    Publication date: June 7, 2018
    Applicant: BIOLOGICAL E LIMITED
    Inventors: Ramesh Venkat Matur, Vivek Babu Kandimalla, Narender Dev Mantena, Mahima Datla, Muthyala Venkateswara Reddy, Kantam Charan
  • Publication number: 20170306302
    Abstract: The present invention relates to high level expression of bacterial toxoid or toxin protein of pharmacological interest by means of an optimized novel polynucleotide sequence and host transformed with the said polynucleotide. Specifically, the invention provides a method for high production of polypeptide CRM197 wherein, the polynucleotide of the invention is used to transform a suitable host resulting in over-expression of corresponding proteins and a method for isolating the expressed polypeptide. More particularly, the present invention relates to high level expression of CRM197 in Escherichia coli and a method for the isolation and purification thereof.
    Type: Application
    Filed: November 17, 2015
    Publication date: October 26, 2017
    Inventors: Akshay Goel, Ravi Pratap Narayan Mishra, Narender Dev Mantena, Mahima Datla
  • Publication number: 20170198004
    Abstract: The present invention relates to novel semi-synthetic meningococcal conjugate vaccine comprising novel synthetic oligosaccharide conjugated to a carrier protein. The present invention also relates to novel synthetic meningococcal oligosaccharide and a process for its preparation.
    Type: Application
    Filed: May 22, 2015
    Publication date: July 13, 2017
    Inventors: Akshay Goel, Santosh Nukuntla, Eswara Kowlakuntla, Mahima Datla, Narendra Dev Mantena